Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHK-Cu (Oral) vs Larazotide
An educational, source-based comparison of GHK-Cu (Oral) and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.
An oral formulation of the GHK-Cu tripeptide designed for systemic absorption. Research suggests the same copper-complex gene-modulating activity as topical forms, potentially supporting systemic tissue repair, immune modulation, and antioxidant capacity.
- Systemic tissue repair and regeneration
- Immune modulation and inflammation
- Lung and gut tissue health
- Age-related gene expression restoration
- • Oral bioavailability is lower than injectable; optimal dosing unclear.
- • Not FDA-approved for therapeutic use.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHK-Cu (Oral) | Oral GHK-Cu absorption and systemic effects | BioMed Research International | 2021 | Detected in plasma after oral administration with modulated inflammatory biomarkers. |
| Larazotide | Larazotide acetate for persistent symptoms of celiac disease | Gastroenterology | 2015 | Reduced symptom severity in gluten-exposed celiac patients on gluten-free diet. |
Side-effect & safety grid
- Oral bioavailability is lower than injectable; optimal dosing unclear.
- Not FDA-approved for therapeutic use.
- Not yet FDA-approved.
- Investigational; physician oversight required.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHK-Cu (Oral) vs Larazotide — Key differences
- Class: GHK-Cu (Oral) is classified as Systemic · Regeneration, while Larazotide is Gastrointestinal · Barrier.
- Primary research focus: GHK-Cu (Oral) — systemic tissue repair and regeneration; Larazotide — celiac disease (phase 3 completed).
- Tag: Systemic · Anti-aging vs Gut.